Enrolling

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine (REBUILD-1)

I5Q-MC-CGAS -

The main purpose of this study is to determine the safety and efficacy of the study drug, galcanezumab, in children with less than 14 headaches per month for three months.

Enter your city or zip code to find the nearest site

See if You May Qualify

Select a location and then answer a few questions or connect with the study site to see if you meet key criteria for this study.

Trial Summary

Age Range
6 - 17 years
Conditions the trial is for
Migraine
What the trial is testing?
Galcanezumab
Could I receive a Placebo?
Yes
Enrollment Goal
325
Trial Dates
Mar 14, 2018 - Nov 2026
How long will I be in the trial?
Your participation could last about 68 weeks and include up to 18 visits to the study center.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have been diagnosed with migraine with or without aura, with a history of migraine headaches for at least 6 months

Participants Must Not:

  • Participants must not be allergic to multiple drugs or certain types of drugs sometimes used for headaches

  • Participants must not have a history of persistent headaches every day or cluster headaches

  • Participants must not have a history of head or neck injury that was associated with the start of migraine headaches or a change in the nature of their headaches

  • Participants must not have a history of brain tumors or birth defects of the brain

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources